Michael Yeadon

691 total citations
17 papers, 455 citations indexed

About

Michael Yeadon is a scholar working on Physiology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Yeadon has authored 17 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 5 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Yeadon's work include Asthma and respiratory diseases (10 papers), Neuropeptides and Animal Physiology (4 papers) and Mast cells and histamine (3 papers). Michael Yeadon is often cited by papers focused on Asthma and respiratory diseases (10 papers), Neuropeptides and Animal Physiology (4 papers) and Mast cells and histamine (3 papers). Michael Yeadon collaborates with scholars based in United Kingdom, Germany and United States. Michael Yeadon's co-authors include Lynn Purkins, Gary Layton, Michael A. Trevethick, Pablo A. Jimenez, Thomas Werfel, Wai M. Liu, Athanasios Tsianakas, Ian H. Osterloh, Christelle Perros-Huguet and Mark E. Bunnage and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Michael Yeadon

17 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Yeadon United Kingdom 11 192 138 110 86 84 17 455
Richard Armer United Kingdom 9 171 0.9× 161 1.2× 67 0.6× 56 0.7× 21 0.3× 27 493
Chantal Cossette Canada 13 201 1.0× 149 1.1× 26 0.2× 45 0.5× 13 0.2× 23 523
Edward J. Kusner United States 10 209 1.1× 120 0.9× 84 0.8× 65 0.8× 12 0.1× 15 402
Angela Styhler Canada 14 132 0.7× 194 1.4× 63 0.6× 17 0.2× 12 0.1× 19 482
Mary G. Huber United States 7 125 0.7× 137 1.0× 52 0.5× 23 0.3× 12 0.1× 9 393
Susumu Tsujimoto Japan 14 95 0.5× 261 1.9× 19 0.2× 19 0.2× 12 0.1× 36 502
E.D. Salter United States 10 160 0.8× 140 1.0× 17 0.2× 39 0.5× 9 0.1× 12 430
Taketoshi Saijo Japan 10 99 0.5× 129 0.9× 34 0.3× 52 0.6× 17 0.2× 24 514
Yusuke Hidaka Japan 8 99 0.5× 252 1.8× 18 0.2× 82 1.0× 14 0.2× 10 653
Cheryl A. Grice United States 12 139 0.7× 347 2.5× 15 0.1× 61 0.7× 10 0.1× 21 665

Countries citing papers authored by Michael Yeadon

Since Specialization
Citations

This map shows the geographic impact of Michael Yeadon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Yeadon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Yeadon more than expected).

Fields of papers citing papers by Michael Yeadon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Yeadon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Yeadon. The network helps show where Michael Yeadon may publish in the future.

Co-authorship network of co-authors of Michael Yeadon

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Yeadon. A scholar is included among the top collaborators of Michael Yeadon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Yeadon. Michael Yeadon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Werfel, Thomas, Gary Layton, Michael Yeadon, et al.. (2018). Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology. 143(5). 1830–1837.e4. 98 indexed citations
2.
Millan, David S., Stephen A. Ballard, Paul A. Glossop, et al.. (2011). Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma. Bioorganic & Medicinal Chemistry Letters. 21(19). 5826–5830. 11 indexed citations
3.
Hewson, Christopher A., Sheena Patel, Luigino Calzetta, et al.. (2011). Preclinical Evaluation of an Inhibitor of Cytosolic Phospholipase A2α for the Treatment of Asthma. Journal of Pharmacology and Experimental Therapeutics. 340(3). 656–665. 30 indexed citations
4.
Mowbray, Charles E., et al.. (2011). The discovery and profile of PF-0868087, a CNS-sparing histamine H3 receptor antagonist for the treatment of allergic rhinitis. MedChemComm. 3(3). 339–343. 5 indexed citations
5.
Millan, David S., Mark E. Bunnage, Jane L. Burrows, et al.. (2011). Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. Journal of Medicinal Chemistry. 54(22). 7797–7814. 76 indexed citations
6.
Glossop, Paul A., David Price, Mark E. Bunnage, et al.. (2010). Inhalation by Design: Novel Ultra-Long-Acting β2-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup. Journal of Medicinal Chemistry. 53(18). 6640–6652. 65 indexed citations
7.
Mantell, Simon J., Peter T. Stephenson, Graham N. Maw, et al.. (2009). SAR of a series of inhaled A2A agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data. Bioorganic & Medicinal Chemistry Letters. 19(15). 4471–4475. 21 indexed citations
8.
Trevethick, Michael A., et al.. (2009). Inhaled muscarinic antagonists for COPD—does an anti-inflammatory mechanism really play a role?. Current Opinion in Pharmacology. 9(3). 250–255. 10 indexed citations
9.
Ulrich, Kristina, Roddy Walsh, Mark Fidock, et al.. (2008). Anti-inflammatory modulation of chronic airway inflammation in the murine house dust mite model. Pulmonary Pharmacology & Therapeutics. 21(4). 637–647. 41 indexed citations
10.
Mantell, Simon J., Peter T. Stephenson, Graham N. Maw, et al.. (2008). Inhaled adenosine A2A receptor agonists for the treatment of chronic obstructive pulmonary disease. Bioorganic & Medicinal Chemistry Letters. 18(4). 1284–1287. 18 indexed citations
11.
Yeadon, Michael, John Preston Parry, Mark S. Yeoman, et al.. (2004). Endothelin-1 Inhibits Mucin Secretion from Ovine Airway Epithelial Goblet Cells. American Journal of Respiratory Cell and Molecular Biology. 31(6). 663–671. 9 indexed citations
12.
Zhu, Jie, Iain Kilty, Elizabeth Gamble, et al.. (2002). Gene Expression and Immunolocalization of 15-Lipoxygenase Isozymes in the Airway Mucosa of Smokers with Chronic Bronchitis. American Journal of Respiratory Cell and Molecular Biology. 27(6). 666–677. 38 indexed citations
13.
Yeadon, Michael & Zuzana Diamant. (1999). New and Exploratory Therapeutic Agents for Asthma. 4 indexed citations
14.
Yeadon, Michael & Zuzana Diamant. (1999). New and Exploratory Therapeutic Agents for Asthma. 2 indexed citations
15.
Yeadon, Michael, et al.. (1995). Induction of calcium‐independent nitric oxide synthase by allergen challenge in sensitized rat lung in vivo. British Journal of Pharmacology. 116(6). 2545–2546. 20 indexed citations
16.
Hodgson, Simon T., et al.. (1993). Design and synthesis of achiral 5-lipoxygenase inhibitors employing the cyclobutyl group. Bioorganic & Medicinal Chemistry Letters. 3(12). 2565–2570. 4 indexed citations
17.
Yeadon, Michael, et al.. (1988). A new method for determination of in vivo pA2 using infusions of naloxone to steady-state blood concentrations. Journal of Pharmacological Methods. 20(1). 29–37. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Armer Breakdown of academic impact, for papers by Chantal Cossette Breakdown of academic impact, for papers by Edward J. Kusner Breakdown of academic impact, for papers by Angela Styhler Breakdown of academic impact, for papers by Mary G. Huber Breakdown of academic impact, for papers by Susumu Tsujimoto Breakdown of academic impact, for papers by E.D. Salter Breakdown of academic impact, for papers by Taketoshi Saijo Breakdown of academic impact, for papers by Yusuke Hidaka Breakdown of academic impact, for papers by Cheryl A. Grice
Rankless by CCL
2026